Nobilis Therapeutics to Present at CapCon 2020 Venture Conference
30 oct. 2020 09h00 HE
|
Nobilis Therapeutics, Inc.
PORTLAND, Ore., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Nobilis Therapeutics, a late stage biotechnology company that is developing a drug-device combination for treatment of psychiatric disorders will...
Nobilis Therapeutics Presents Its PTSD Clinical Development Program To The US Congress
23 févr. 2018 15h19 HE
|
Nobilis Therapeutics, Inc.
WASHINGTON, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Dr. Edward Meloni, PhD of McLean Hospital (Harvard Medical School Affiliate) and Dr. Vlad Bogin, CEO and Founder of Nobilis Therapeutics earlier this...
Nobilis Therapeutics’ NBTX-001 shows promise in treatment of patients with Panic Disorder
14 juin 2017 13h34 HE
|
Nobilis Therapeutics, Inc.
PORTLAND, Ore., June 14, 2017 (GLOBE NEWSWIRE) -- Nobilis Therapeutics, Inc. announced today that the results of the clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in...
Nobilis Therapeutics Receives a Notice of Allowance for a Patent Covering Treatment of Psychiatric Disorders With Noble Gases
12 juin 2017 18h57 HE
|
Nobilis Therapeutics, Inc.
PORTLAND, Ore., June 12, 2017 (GLOBE NEWSWIRE) -- Nobilis Therapeutics announced today that the patent that it had exclusively licensed from Partners HealthCare/McLean Hospital (an affiliate of...